发明公开
EP2739615A1 PHENYL-3-AZA-BICYCLO[3.1.0]HEX-3-YL-METHANONES AND THE USE THEREOF AS MEDICAMENT
有权
苯甲酰基-3-AZA-BICYCLO [3.1.0] HEX-3-YL-METHANONE UND DEREN VERWENDUNG ALS MEDIKAMENT
- 专利标题： PHENYL-3-AZA-BICYCLO[3.1.0]HEX-3-YL-METHANONES AND THE USE THEREOF AS MEDICAMENT
- 专利标题（中）： 苯甲酰基-3-AZA-BICYCLO [3.1.0] HEX-3-YL-METHANONE UND DEREN VERWENDUNG ALS MEDIKAMENT
-
申请号： EP12741022.3申请日： 2012-08-02
-
公开(公告)号： EP2739615A1公开(公告)日： 2014-06-11
- 发明人: GIOVANNINI, Riccardo , BERTANI, Barbara , FERRARA, Marco , LINGARD, Iain , MAZZAFERRO, Rocco , ROSENBROCK, Holger
- 申请人： Boehringer Ingelheim International GmbH
- 申请人地址： Binger Strasse 173 55216 Ingelheim am Rhein DE
- 专利权人： Boehringer Ingelheim International GmbH
- 当前专利权人： Boehringer Ingelheim International GmbH
- 当前专利权人地址： Binger Strasse 173 55216 Ingelheim am Rhein DE
- 代理机构： Simon, Elke Anna Maria
- 优先权： EP11176468 20110803
- 国际公布： WO2013017657 20130207
- 主分类号： C07D401/04
- IPC分类号： C07D401/04 ; C07D403/04 ; C07D413/04 ; C07D413/14 ; C07D417/04 ; C07D471/04 ; A61K31/421 ; A61K31/427 ; A61K31/437 ; A61K31/4439 ; A61P25/18 ; A61P25/28
摘要：
The present inventions relates to substituted phenyl-3-aza-bicyclo[3.1.0]hex-3-yl- methanones of general formula (I) wherein R
1 , R
2 , R
3 , R
4 , R
5 and R
6 are as herein described or salts thereof, preferably pharmaceutically acceptable salts thereof. The invention further relates to the manufacture of said compounds, pharmaceutical compositions comprising a compound according to general formula (I), and the use of said compounds for the treatment of various conditions such as conditions concerning positive and negative symptoms of schizophrenia as well as cognitive impairments associated with schizophrenia, Alzheimers Disease and other neurological and psychiatric disorders. The compounds of the invention show glycine transporter-1 (GlyT1) inhibiting properties.
1 , R
2 , R
3 , R
4 , R
5 and R
6 are as herein described or salts thereof, preferably pharmaceutically acceptable salts thereof. The invention further relates to the manufacture of said compounds, pharmaceutical compositions comprising a compound according to general formula (I), and the use of said compounds for the treatment of various conditions such as conditions concerning positive and negative symptoms of schizophrenia as well as cognitive impairments associated with schizophrenia, Alzheimers Disease and other neurological and psychiatric disorders. The compounds of the invention show glycine transporter-1 (GlyT1) inhibiting properties.
公开/授权文献
信息查询
